SCHEMBL2002901

SCHEMBL2002901

C[C@H](c1ccc(Br)cc1)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
DNMT3A Q9Y6K1 1/20 0.47
TDP1 Q9NUW8 1/20 0.45
GSK3B P49841 1/20 0.41
TP53 P04637 1/20 0.40
MAPK1 P28482 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD11B1 P28845 1/20 0.40
ALDH1A1 P00352 3/20 0.40
CASP3 P42574 1/20 0.40
MAPT P10636 1/20 0.40
POLB P06746 1/20 0.40
DNMT1 P26358 1/20 0.40
HTT P42858 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31706143 1.00 LMNA (0.47) LMNADNMT3ATDP1GSK3BTP53
SCHEMBL14729729 1.00 LMNA (0.47) LMNADNMT3ATDP1GSK3BTP53
SCHEMBL2002904 1.00 LMNA (0.47) LMNADNMT3ATDP1GSK3BTP53
SCHEMBL14280267 0.86 DNMT3A (0.42) LMNADNMT3AHSD11B1ALDH1A1POLB
SCHEMBL10926240 0.85 ALDH1A1 (0.51) LMNATDP1NPSR1ALDH1A1CASP3
SCHEMBL16356142 0.85 ALDH1A1 (0.51) LMNATDP1NPSR1ALDH1A1CASP3
SCHEMBL6925572 0.85 LMNA (0.58) LMNADNMT3ATDP1TP53ALDH1A1
SCHEMBL29393294 0.85 LMNA (0.58) LMNADNMT3ATDP1TP53ALDH1A1
SCHEMBL607042 0.85 LMNA (0.58) LMNADNMT3ATDP1TP53ALDH1A1
SCHEMBL12184795 0.82 LMNA (0.47) LMNATDP1TP53MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960365-B2 Compounds with medicinal effects due to interaction with the glucocorticoid receptor N.V. ORGANON (NL) 2011-06-14 US disclosed
US-20070149577-A1 Compounds with medicinal effects due to interaction with the glucocorticoid receptor N.V. ORGANON (NL) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149577-A1 Compounds with medicinal effects due to interaction with the glucocorticoid receptor NR3C1, NR3C2, MC2R LMNA 3879/4885DNMT3A 3435/4885TDP1 3950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.